Publications by authors named "Iris Kloots"
PSMA-targeting radioligand therapy (PSMA-RLT) has shown promise in metastatic castration-resistant prostate cancer (mCRPC), particularly in PSMA-avid tumours. However, predicting response remains challenging. Preclinical data suggests aberrant p53-signalling as a predictor of poor response.
View Article and Find Full Text PDFArticle Synopsis
- Immune checkpoint inhibitors (ICIs) are effective for some metastatic urothelial cancer (mUC) patients, but only 20-25% see a durable response.
- A study investigated the potential of measuring circulating tumor DNA (ctDNA) levels during treatment to predict responsiveness to ICIs in mUC patients, using a discovery cohort of 40 and a validation cohort of 16.
- Results showed that increases in ctDNA at 3 and 6 weeks were strongly associated with shorter progression-free survival and overall survival, indicating that early ctDNA changes could guide better management of treatment strategies.
Patients with metastatic castration-resistant prostate cancer (mCRPC) harbouring homologous recombination repair-related gene aberrations (HRRm) can derive meaningful benefits from both platinum-based chemotherapy (PlCh) and PARP inhibitors (PARPi). Cross-resistance between these agents is well-recognised in other tumour types but data on prostate cancer is lacking. In this retrospective pre-planned study, we assessed 28 HRRm mCRPC patients who received PlCh and PARPi.
View Article and Find Full Text PDFArticle Synopsis
- The use of circulating tumor cells (CTCs) is gaining recognition as a non-invasive biomarker for cancer diagnosis and treatment.
- Traditional methods for isolating CTCs focus on specific proteins, which can overlook the diversity of cancer cells and limit their prognostic value.
- A new approach using size and deformability for CTC enrichment, specifically with the FDA-approved Parsortix technology, allows for better characterization and may help predict patient responses to therapy in metastatic castration-resistant prostate cancer (mCRPC).
Article Synopsis
- * A panel of 39 Dutch experts used a modified Delphi method to discuss and vote on the appropriateness of testing, reaching consensus on only 44% of their questions.
- * Key findings suggest that patients with a family history might benefit from certain types of genetic testing, but limitations include a lack of scientific evidence for some recommendations and a limited number of specialists involved in the discussions.
Background: Molecular tumour boards (MTB) optimally match oncological therapies to patients with genetic aberrations. Prostate cancer (PCa) is underrepresented in these MTB discussions. This study describes the impact of routine genetic profiling and MTB referral on the outcome of PCa patients in a tertiary referral centre.
View Article and Find Full Text PDFPurpose: Although most patients with microsatellite instable (MSI) metastatic castration-resistant prostate cancer (mCRPC) respond to immune checkpoint blockade (ICB), only a small subset of patients with microsatellite stable (MSS) tumors have similar benefit. Biomarkers defining ICB-susceptible subsets of patients with MSS mCRPC are urgently needed.
Methods: Using next-generation T-cell repertoire sequencing, we explored immune signatures in 54 patients with MSS and MSI mCRPC who were treated with or without ICB.
Platinum-based chemotherapy is not standard of care for unselected or genetically selected metastatic castration-resistant prostate cancer (mCRPC) patients. A retrospective assessment of 71 patients was performed on platinum use in the Netherlands. Genetically unselected patients yielded low response rates.
View Article and Find Full Text PDF